Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara et al. · The Lancet Oncology · 2008 · 1.9K citations

Surgical Oncology, Spirits Trial, Gastrointestinal Oncology +8

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 819 citations

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham, István Láng, Eugenio Marcuello et al. · The Lancet Oncology · 2013 · 642 citations

Elderly Patients, Gastrointestinal Oncology, Medicine +10

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

Miriam Koopman, Ninja Antonini, Joep Douma et al. · The Lancet · 2007 · 626 citations

Gastrointestinal Oncology, Medicine, Phase Iii +8

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

Jim Cassidy, Chris Twelves, Eric Van Cutsem et al. · Annals of Oncology · 2002 · 521 citations

Oncology, Gastrointestinal Oncology, Cancer Management +6